There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

The stock experienced a severe reaction following the preliminary data announcement from cohort A of the Ascend trial, indicating potential market misinterpretation. Lisata Therapeutics Inc ...

Lisata Therapeutics Inc (NASDAQ:LSTA) has advanced its development portfolio, particularly with its novel product candidate, certepatide, for treating advanced solid tumors. Preliminary results from ...

Lisata is also partnering with Valo Therapeutics (ValoTx) to investigate the benefits ... This was primarily due to a reduction in expenses associated with the Phase 2b ASCEND trial which completed ...

Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming monthsEnrollment ...

As mentioned on prior calls, the ASCEND trial is an investigator initiated trial that Lisata inherited upon our acquisition of Cend Therapeutics. The original trial was designed with more of an ...

Portland Police responded to a stabbing call in the 3900 block of North Vancouver Avenue early Wednesday morning. Officers were dispatched at 5:41 a.m. to the Ascend Apartments at Failing Street and ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...

The Financial Times, citing industry sources, reports that Huawei's Ascend 910C, manufactured using the SMIC 7nm (N+2) process, has improved its yield rate to nearly 40%, making the Ascend ...